Pfizer's experimental lung cancer drug fails to extend survival in late-stage trial
Colleen Cabi
·
2026-06-23
·
via Quartz
The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703…
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。